Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
1276- SIL,    Silibinin inhibits TPA-induced cell migration and MMP-9 expression in thyroid and breast cancer cells
- in-vitro, BC, NA - in-vitro, Thyroid, NA
TumCMig↓, MMP9↓, p‑MEK↓, p‑ERK↓,
1316- SIL,  Chemo,    Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity
- Analysis, Var, NA
TumCCA↑, p42↓, P450↓, OATPs↓, chemoP↑, ChemoSen↑,
4206- SIL,    Silymarin ameliorates experimentally induced depressive like behavior in rats: Involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response
- in-vivo, NA, NA
*BDNF↑, *5HT↑, *antiOx↑, *IL6↓, *TNF-α↓, *Mood↑,
4205- SIL,    The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review
- Review, AD, NA
*BDNF↑, *5HT↑, *MDA↓, *GSH↑, *SOD↑, *Catalase↑, *IL6↓, *IL1β↓,
4207- SIL,    Silymarin sex-dependently improves cognitive functions and alters TNF-α, BDNF, and glutamate in the hippocampus of mice with mild traumatic brain injury
*TNF-α↓, *BDNF↑, *cognitive↑,
109- SIL,    Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma
- vitro+vivo, RCC, 769-P - in-vitro, RCC, 786-O - in-vitro, RCC, ACHN - in-vitro, RCC, OS-RC-2
HH↓, Gli1↓, GLI2↓, mTOR↓, Bcl-2↓, Apoptosis↑, Casp3↑, PARP↑, TumCG↓,
1140- SIL,    Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth
- in-vitro, PC, AsPC-1 - in-vivo, PC, NA - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
TumCG↓, Glycolysis↓, cMyc↓, STAT3↓, TumCP↓, Weight∅, Strength↑, DNAdam↑, Casp3↑, Casp9↑, GLUT1↓, HK2↓, LDHA↓, GlucoseCon↓, lactateProd↓, PPP↓, Ki-67↓, p‑STAT3↓, cachexia↓,
1127- SIL,    Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,
964- SIL,    Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics
- vitro+vivo, Pca, LNCaP - in-vitro, Pca, 22Rv1
TumCP↓, Hif1a↓, NADPH↓, angioG↓, FASN↓, ACC↓,
1001- SIL,    Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
- in-vitro, NA, NA
TumCG↓, Glycolysis↓, OXPHOS↑, LDHA↓, lactateProd↓, i-citrate↑, Hif1a↓, PD-L1↓,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,
2306- SIL,  CUR,  RES,  EA,    Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment
- in-vitro, BC, MDA-MB-231
PKM2↓, Dose↝, Dose↝,
2410- SIL,    Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF
- in-vitro, GBM, U87MG - in-vitro, GBM, U251 - in-vivo, NA, NA
TumAuto↑, ATP↓, Glycolysis↓, H2O2↑, P53↑, GSH↓, xCT↓, BNIP3↝, MMP↑, mt-ROS↑, mtDam↑, HK2↓, PFKP↓, PKM2↓, TumCG↓,
4122- Silicon,    Silicon-rich mineral water as a non-invasive test of the 'aluminum hypothesis' in Alzheimer's disease
- Trial, AD, NA
*other↓, *other∅, *cognitive↑,
4123- Silicon,    The potential influence of silica present in drinking water on Alzheimer's disease and associated disorders
- Review, AD, NA
*Aβ↓, *cognitive↝,
4136- Silicon,    Aluminum Should Now Be Considered a Primary Etiological Factor in Alzheimer’s Disease
- Review, AD, NA
*cognitive↑, *Risk↓, *neuroP↑,
4134- Silicon,    Garden Cress (Lepidium sativum) Seeds Ameliorated Aluminum-Induced Alzheimer Disease in Rats Through Antioxidant, Anti-Inflammatory, and Antiapoptotic Effects
- in-vivo, AD, NA
*neuroP↑, *BioAv↓, *cognitive↑,
4133- Silicon,    Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study
- Study, AD, NA
*Risk↓, *Dose↑, *neuroP↑,
4131- Silicon,    Silicon reduces aluminum accumulation in rats: relevance to the aluminum hypothesis of Alzheimer disease
- Study, Nor, NA
*other↓, *BioAv↓, *neuroP↑,
4129- Silicon,    Silica and aluminum in drinking water and cognitive impairment in the elderly
- Study, AD, NA
*cognitive↑,
4125- Silicon,    Oral silicon supplementation: an effective therapy for preventing oral aluminum absorption and retention in mammals
- Review, AD, NA
*neuroP↑, *BioAv↓,
4126- Silicon,  H2,    Oral Administration of Si-Based Agent Attenuates Oxidative Stress and Ischemia-Reperfusion Injury in a Rat Model: A Novel Hydrogen Administration Method
- in-vivo, NA, NA
*creat↓, *ROS↓, *other↑, *MDA↓, *other↑, *Inflam↓,
4128- Silicon,    Silicon as Versatile Player in Plant and Human Biology: Overlooked and Poorly Understood
- Review, NA, NA
*other↑, *BMD↑, *Dose↝, *cognitive↑, *Dose?,
4127- Silicon,    Interference of Parenteral Nutrition Components in Silicon-Mediated Protection Against Aluminum Bioaccumulation
- in-vivo, AD, NA
*other↓, *neuroP↑,
2359- SK,    Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
- in-vivo, Liver, NA
TumCG↓, PKM2↓, EMT↓, TGF-β↓, Glycolysis↓, lactateProd↓, ATP↓,
2420- SK,    Pyruvate kinase M2 regulates mitochondrial homeostasis in cisplatin-induced acute kidney injury
- in-vivo, AKI, NA
PKM2↓, other↝,
2419- SK,    Regulation of glycolysis and the Warburg effect in wound healing
- in-vivo, Nor, NA
Glycolysis↓, GLUT1↓, GLUT3↓, HK2↓, HK1↓, PFK1↓, PFK2↓, PKM2↓, lactateProd↓, GlucoseCon↓,
2418- SK,    Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2
- in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, HUH7 - in-vitro, HCC, HepG2
tumCV↓, GlucoseCon↓, lactateProd↓, ChemoSen↑, PKM2↓, Glycolysis↓,
2417- SK,    Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H446
TumCP↓, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, PFKFB2↓, Warburg↓, GLUT1∅, LDHA∅, PKM2∅, GLUT3∅, PDH∅,
2416- SK,    Shikonin induces cell death by inhibiting glycolysis in human testicular cancer I-10 and seminoma TCAM-2 cells
- in-vitro, Testi, TCAM-2
MMP↓, ROS↑, lactateProd↓, Bcl-2↓, cl‑Casp3↓, PKM2↓, GLUT1↓, HK2↓, LC3B↑,
2415- SK,    Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways
- in-vivo, Arthritis, NA
Apoptosis?, TumAuto↑, ROS↑, ATP↓, Glycolysis↓, PI3K↓, Akt↓, mTOR↓, *Apoptosis↓, *Inflam↓, *TNF-α↓, *IL6↓, *IL8↓, *IL10↓, *IL17↓, *hepatoP↑, *RenoP↑, PKM2↓, GLUT1↓, HK2↓,
2354- SK,    PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation
- in-vivo, Sepsis, NA
PKM2↓, *PKM2↓, *IL1β↓, *IL18↓, *HMGB1↓, *Casp1↓, *NLRP3↓, *AIM2↓, *p‑eIF2α↓, *Sepsis↓,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
2370- SK,    The role of pyruvate kinase M2 in anticancer therapeutic treatments
- Review, Var, NA
Glycolysis↓, PKM2↓, EGFR↓, PI3K↓, p‑Akt↓, Hif1a↓,
2356- SK,    ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment
- in-vitro, Ovarian, CaOV3 - in-vitro, Ovarian, OV90 - in-vivo, NA, NA
PKM2↓, Glycolysis↓, FASN↓, lactateProd↓, Warburg↓, TumCG↓, VM↓,
2357- SK,    GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism
- Study, HCC, NA - in-vivo, NA, NA
AntiTum↑, GTPBP4↓, PKM2↓, lactateProd↓, GlucoseCon↓, Glycolysis↓, E-cadherin↑, TumCG↓,
2358- SK,    SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2
- in-vivo, Park, NA
*eff↑, *PKM2↓, *motorD↑, *lactateProd↓,
2360- SK,    Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway
- in-vitro, NPC, HONE1 - in-vitro, NPC, SUNE-1
TumCP↓, Apoptosis↑, TumCMig↓, TumCI↓, GlucoseCon↓, lactateProd↓, ATP↓, PKM2↓, PI3K↓, Akt↓, MMP3↓, MMP9↓, TIMP1↑,
2361- SK,    Natural shikonin and acetyl-shikonin improve intestinal microbial and protein composition to alleviate colitis-associated colorectal cancer
- in-vivo, CRC, NA
GutMicro↑, Dose↝, IL1β↓, IL6↓, TNF-α↓, PKM2↓,
2362- SK,    RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide
- in-vitro, GBM, U87MG - in-vivo, GBM, NA - in-vitro, GBM, U251
RIP1↑, RIP3↑, Glycolysis↓, G6PD↓, HK2↓, PKM2↓, H2O2↑, GSH↓, ROS↑,
2363- SK,    Inhibition of PKM2 by shikonin impedes TGF-β1 expression by repressing histone lactylation to alleviate renal fibrosis
- in-vivo, CKD, NA
PKM2↓, lactateProd↓, TGF-β↓,
2364- SK,    Pyruvate Kinase M2 Mediates Glycolysis Contributes to Psoriasis by Promoting Keratinocyte Proliferation
- in-vivo, PSA, NA
eff↑, lactateProd↓, PKM2↓,
2211- SK,    Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways
- in-vivo, ostP, NA
*BMD↑, *p‑NF-kB↓, *p‑p50↓, *p‑p65↓, *p‑ERK↓, *p‑cJun↓, *p‑p38↓,
2234- SK,    Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1
- in-vitro, GC, NA
TumCP↓, TumCI↓, TumCMig↓, cMyc↓, YAP/TEAD↓,
2233- SK,    Clinical trial on the effects of shikonin mixture on later stage lung cancer
- Trial, Lung, NA
TumVol↓, Remission↑, OS↑, QoL↑, Weight↑, *toxicity∅,
2232- SK,    Shikonin Induces Autophagy and Apoptosis in Esophageal Cancer EC9706 Cells by Regulating the AMPK/mTOR/ULK Axis
- in-vitro, ESCC, EC9706
tumCV↓, TumCMig↓, TumCI↓, TumAuto↑, Apoptosis↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, AMPK↑, mTOR↑, TumVol↓, OS↑, LC3I↑,
2231- SK,    Shikonin Exerts Cytotoxic Effects in Human Colon Cancers by Inducing Apoptotic Cell Death via the Endoplasmic Reticulum and Mitochondria-Mediated Pathways
- in-vitro, CRC, SNU-407
Apoptosis↑, ER Stress↑, PERK↑, eIF2α↑, CHOP↑, mt-Ca+2↑, MMP↓, Bcl-2↓, Casp3↑, Casp9↑, ERK↑, JNK↑, p38↓,
2230- SK,    Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCG↓, Bcl-2↓, ROS↑, Bcl-xL↓, MMP↓, Casp↑, selectivity↑, cycD1/CCND1↓, TumCCA↑, eff↓,

Showing Research Papers: 5401 to 5450 of 6149
Prev Page 109 of 123 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6149

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 2,   GSH↑, 1,   H2O2↑, 2,   HK1↓, 1,   lipid-P↓, 1,   OXPHOS↑, 1,   ROS↓, 1,   ROS↑, 6,   mt-ROS↑, 1,   TrxR1↓, 1,   xCT↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 5,   MEK↓, 1,   p‑MEK↓, 1,   MMP↓, 5,   MMP↑, 1,   mtDam↑, 1,   p42↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACC↓, 1,   AMPK↑, 1,   i-citrate↑, 1,   cMyc↓, 3,   FASN↓, 2,   G6PD↓, 1,   GlucoseCon↓, 6,   Glycolysis↓, 11,   HK2↓, 6,   lactateProd↓, 12,   LDHA↓, 2,   LDHA∅, 1,   NADPH↓, 1,   PDH∅, 1,   PFK1↓, 1,   PFK2↓, 1,   PFKFB2↓, 1,   PFKP↓, 1,   PKM2↓, 18,   PKM2∅, 1,   PPP↓, 1,   SIRT1↓, 1,   SREBP1↓, 1,   Warburg↓, 2,  

Cell Death ⓘ

Akt↓, 5,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis?, 1,   Apoptosis↑, 6,   ATF2↓, 1,   BAX↑, 2,   Bcl-2↓, 6,   Bcl-xL↓, 2,   BID↑, 1,   BIM↓, 1,   Casp↑, 3,   Casp3↑, 6,   cl‑Casp3↓, 1,   cl‑Casp3↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 3,   Cyt‑c↑, 2,   GRP58↓, 1,   hTERT/TERT↓, 1,   JNK↑, 1,   p‑JNK↑, 1,   MAPK↓, 2,   Necroptosis↑, 1,   p27↑, 1,   p38↓, 1,   p‑p38↑, 1,   RIP1↓, 1,   RIP1↑, 1,   survivin↓, 2,   Telomerase↓, 1,   YAP/TEAD↓, 2,  

Transcription & Epigenetics ⓘ

HATs↑, 2,   miR-21↓, 1,   other↝, 1,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   eIF2α↑, 1,   ER Stress↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes ⓘ

BNIP3↝, 1,   LC3B↑, 1,   LC3I↑, 1,   LC3II↑, 1,   TumAuto↑, 4,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   DNMT1↓, 1,   P53↑, 3,   PARP↑, 1,   cl‑PARP↑, 2,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 3,   P21↑, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   EMT↓, 4,   ERK↓, 3,   ERK↑, 1,   p‑ERK↓, 2,   Gli1↓, 1,   GTPBP4↓, 1,   HDAC↓, 2,   HH↓, 1,   IGFBP3↑, 1,   mTOR↓, 4,   mTOR↑, 1,   NOTCH↓, 1,   PI3K↓, 6,   Src↓, 1,   STAT3↓, 2,   p‑STAT3↓, 1,   STAT5↓, 1,   TumCG↓, 9,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

Akt2↓, 1,   AP-1↓, 1,   CA↓, 1,   Ca+2↑, 1,   mt-Ca+2↑, 1,   CD31↓, 1,   E-cadherin↑, 2,   FAK↓, 2,   GLI2↓, 1,   Ki-67↓, 1,   miR-155↓, 1,   miR-203↑, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 4,   MMPs↓, 2,   PDGF↓, 1,   RHBDD1↓, 1,   RIP3↓, 1,   RIP3↑, 1,   TGF-β↓, 3,   TIMP1↑, 1,   TumCI↓, 5,   TumCMig↓, 8,   TumCP↓, 8,   TumMeta↓, 1,   uPA↓, 2,   Vim↓, 1,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 3,   EGFR↓, 2,   p‑EGFR↓, 1,   Hif1a↓, 5,   VEGF↓, 3,   VEGFR2↓, 1,   VM↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 4,   GLUT1∅, 1,   GLUT3↓, 1,   GLUT3∅, 1,   NHE1↓, 1,   OATPs↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IFN-γ↑, 1,   IL1↓, 1,   IL10↓, 1,   IL1β↓, 1,   IL2↑, 1,   IL6↓, 1,   Inflam↓, 1,   JAK2↓, 1,   MDSCs↓, 1,   NF-kB↓, 2,   PD-L1↓, 2,   PGE2↓, 1,   PSA↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   ChemoSen↑, 2,   Dose↝, 4,   eff↓, 1,   eff↑, 1,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   P450↓, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

AR↓, 1,   EGFR↓, 2,   p‑EGFR↓, 1,   GutMicro↑, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   Ki-67↓, 1,   PD-L1↓, 2,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   cachexia↓, 1,   cardioP↑, 2,   chemoP↑, 3,   hepatoP↑, 2,   neuroP↑, 1,   OS↑, 2,   QoL↑, 1,   Remission↑, 1,   Strength↑, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 2,   Weight↑, 1,   Weight∅, 1,  
Total Targets: 213

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   GSH↑, 1,   MDA↓, 2,   ROS↓, 1,   SOD↑, 1,  

Core Metabolism/Glycolysis ⓘ

lactateProd↓, 1,   PKM2↓, 2,   SIRT1↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   Casp1↓, 1,   p‑p38↓, 1,  

Transcription & Epigenetics ⓘ

p‑cJun↓, 1,   other↓, 3,   other↑, 3,   other∅, 1,  

Protein Folding & ER Stress ⓘ

p‑eIF2α↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,  

Migration ⓘ

TIMP1↓, 1,  

Immune & Inflammatory Signaling ⓘ

AIM2↓, 1,   HMGB1↓, 1,   IL10↓, 1,   IL17↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL6↓, 3,   IL8↓, 2,   Inflam↓, 3,   p‑NF-kB↓, 1,   p‑p50↓, 1,   p‑p65↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission ⓘ

5HT↑, 2,   BDNF↑, 3,  

Protein Aggregation ⓘ

Aβ↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   Dose?, 1,   Dose↑, 1,   Dose↝, 1,   eff↑, 1,  

Clinical Biomarkers ⓘ

BMD↑, 2,   creat↓, 1,   IL6↓, 3,  

Functional Outcomes ⓘ

cognitive↑, 6,   cognitive↝, 1,   hepatoP↑, 1,   Mood↑, 1,   motorD↑, 1,   neuroP↑, 6,   RenoP↑, 1,   Risk↓, 2,   toxicity∅, 1,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 54

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page